Highly selective virus to treat refractary tumors
Manel Cascalló Ph.D. CEO
Address: Av. de la Generalitat 152.
City: 08174 Sant Cugat del Vallès.
Province: Barcelona
Phone: 34 93 571 2359
Fax: 34 935712129
Mission and Objectives
VCN Biosciences mission is the development of new agents for the treatment of cancer based on oncolytic adenoviruses with high potency and selectivity. The company develops new candidate viruses from its design, preclinical studies, and early efficacy studies in humans (Phase I and II clinical trials).
Products/Services, Areas of interest for future collaborations/Alliances
VCN Biosciences SL is a company focused in the development of new therapeutic approaches for tumors that lack effective treatment. The company uses an oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumor cells. The selectivity of VCN oncolytic adenoviruses allows their systemic administration, which is especially relevant for the treatment of disseminated cancer. Contrary to chemotherapy, the ability of oncolytic virus to self-amplify in tumor cells results in an effective dose increase with time. These properties highlight VCN candidates as promising alternatives for the treatment of refractory tumors such as pancreatic adenocarcinomas or melanoma, which are some of the current tumor targets of VCN Biosciences.

Developed by Web4Bio